Literature DB >> 3078708

Inherited deficiency of the fourth component of human complement.

G Hauptmann1, G Tappeiner, J A Schifferli.   

Abstract

The highly polymorphic fourth component of human complement (C4) is usually encoded by two genes, C4A and C4B, adjacent to the 21-hydroxylase (21-OH) genes, and is also remarkable by the high frequency of the null alleles, C4A*Q0 and C4B*Q0. Despite considerable structural homology, the gene products of the two loci differ in hemolytic activities, antigenic reactivities and covalent binding affinities to antigens and antibodies. Complete C4 deficiency is exceptional because this condition appears only in homozygotes for the very rare double-null haplotype C4AQ0,BQ0. In contrast, partial C4 deficiency is a common immune protein defect in all human populations as a consequence of the high frequency of the C4 half-null haplotypes. Complete C4 deficiency in most cases gives rise to SLE and an increased susceptibility to infections, and partial C4 deficiencies predispose to different auto-immune diseases related to extended HLA haplotypes bearing the C4 half-null haplotypes. Studies at the DNA level have shown that about half of the null alleles are due to deletions involving C4A and 21-OHA, C4B and 21-OHA or C4B and 21-OHB. Larger deletions including both C4A and C4B genes have never been observed. Partial C4 deficiency may be observed in combination with other complement deficiencies or immune defects, and allo- or auto-anti-C4 immunization is also a possible consequence of this genetic abnormality. Although the pathogenesis of the diseases related to complete and partial C4 deficiencies is not yet clearly understood, it is evident that C4 null alleles represent interesting markers and additive risk factors for autoimmune phenomena.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3078708

Source DB:  PubMed          Journal:  Immunodefic Rev        ISSN: 0893-5300


  31 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  HLADR5 and C4BQO high frequency and antinuclear antibodies positivity in patients with 21 hydroxylase deficiency from Campania region.

Authors:  F Parlato; G Pisano; G Misiano; E Cosentini; C Cacciapuoti; M R Cavalcanti; M Brai; A Bellastella
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

3.  A unique recombination event resulting in a C4A*Q0,C4B*Q0 double null haplotype.

Authors:  M B Fasano; J A Winkelstein; T LaRosa; W B Bias; R H McLean
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

4.  Nephrosis, peritonitis and complement deficiency.

Authors:  D G Matsell; S Roy; J A Bin; R J Wyatt
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

5.  Circulating immune complexes and complement C4 null alleles in patients in patients operated on for premature atherosclerotic peripheral vascular disease.

Authors:  S Nityanand; L Truedsson; A Mustafa; C Bergmark; A K Lefvert
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

6.  Novel detection of restriction fragment length polymorphisms in the human major histocompatibility complex.

Authors:  S J Cross; S Tonks; J Trowsdale; R D Campbell
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

7.  Deficiency of mannan binding protein--a new complement deficiency syndrome.

Authors:  M W Turner
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

8.  Defining targets for complement components C4b and C3b on the pathogenic neisseriae.

Authors:  Lisa A Lewis; Sanjay Ram; Alpana Prasad; Sunita Gulati; Silke Getzlaff; Anna M Blom; Ulrich Vogel; Peter A Rice
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

9.  Association of C4B deficiency (C4B*Q0) with erythema nodosum in leprosy.

Authors:  I J de Messias; J Santamaria; M Brenden; A Reis; G Mauff
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  DNase I hypersensitivity mapping and promoter polymorphism analysis of human C4.

Authors:  A K Vaishnaw; R Hargreaves; R D Campbell; B J Morley; M J Walport
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.